Medical Diagnostics News

Creative Enzymes Launches DSPE-PEG-Maleimide for Targeted Drug Delivery

Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzymes as many as possible. The product manager of Creative Enzymes announced the launch of DSPE-PEG(5000) Maleimide and DSPE-PEG(2000) Maleimide, which can be used to synthesize functional conjugates. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a ...

Jun. 22, 2021

By Creative Enzymes

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Program Call for Submissions to Support Research in Immuno-oncology

Thermo Fisher Scientific today announced that submissions are now open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. This grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients. Through the Oncomine Clinical Research Grant program, Thermo Fisher will ...

Jun. 16, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Part of the Cell and Gene Therapy Catapult PAT Consortium

Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve ...

Jun. 9, 2021

By Imspex Diagnostics Ltd.

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...

May 25, 2021

By Creative Enzymes

FlavourSpec feasibly detects hepatocellular carcinoma urinary biomarkers in clinical practice

The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds ...

May 6, 2021

By Imspex Diagnostics Ltd.

Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. ...

May 3, 2021

By Novavax

Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research

As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...

Apr. 28, 2021

By Creative Biolabs

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...

Apr. 28, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

MediPines AGM100 Voted as Finalist in Medical Design Excellence Awards, MDEA 2021

We are pleased to announce that MediPines AGM100, a non-invasive pulmonary gas exchange analyzer, was selected as a finalist in the 2021 Medical Design Excellence Awards (MDEA). The MDEAs is the premier design competition in the MedTech industry organized by MD+DI and recognizes the significant achievements in medical product design and engineering that improve the quality of healthcare delivery ...

Apr. 27, 2021

By MediPines

Dutch Secretary of State visits Xeltis following RegMedXB funding

The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners. Minister Mona Keijzer met executives from the RegMedXB private-public partnership, which recently secured funding for up to €56 million from the Dutch National Growth Fund to build an infrastructure ...

Apr. 26, 2021

By XELTIS BV

Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, ...

Apr. 16, 2021

By Creative Biolabs

Smiths Detection announces University of Maryland, Baltimore County successfully deploys BioFlash for airborne detection of SARS-CoV-2

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that its BioFlash Biological Identifier has been successfully used by the University of Maryland, Baltimore County (UMBC) to identify airborne SARS-CoV-2 inside their campus in real-time at the point of testing. As part of their mitigation strategy for COVID-19, UMBC’s Environmental ...

Apr. 13, 2021

By Smiths Detection Inc.

AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

Our AACR Presentation #1731 is now available. Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. While the advent of these inhibitors has brought significant benefit to patients with ...

Apr. 12, 2021

By Exscientia

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients ...

Apr. 9, 2021

By Exscientia

Proud to be supporting the COVID-19 vaccine supply chain in the United Kingdom

Puretech’s AquaZero distillation system was recently supplied to Scotland based contract manufacturing organisation Andersen Caledonia. The system will enable the company to wash glass vials prior to sterile packing in its ISO 5 cleanroom. The vials will then be supplied to be filled with vaccines. The AquaZero Still generates Water for Injection (WFI) and Pure Steam (PS) at ...

Apr. 7, 2021

By Puretech Process Systems Limited

India’s HealthPlix raises $13.5 million to help doctors treat patients more efficiently

There are fewer than 300,000 doctors in India actively practicing medicine. They serve hundreds of millions of patients who suffer from chronic illness in the world’s second-most populous nation. A doctor only has a few minutes to spend on a patient, remember the past diagnosis by glancing at their record and formulate a plan of management. HealthPlix, a Bangalore-based startup, believes ...

Mar. 31, 2021

By HealthPlix Technologies Private Limited

Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum ...

Mar. 30, 2021

By Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.

Sysmex Continues to Evolve Its Hematology Product Portfolio

Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer (“XN-Series”) in 2011, combining modules for blood count, smear ...

Mar. 29, 2021

By Sysmex Corporation

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...

Mar. 29, 2021

By Eli Lilly and Company

Study published in BJC shows strong performance of Tethis’ liquid biopsy test in early stage breast cancer

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® ...

Mar. 24, 2021

By Tethis S.p.A